Harvard Bioscience, Inc. (FRA:HBI)

Market Cap	22.14M -68.1%
Revenue (ttm)	74.47M -10.6%
Net Income	-45.88M
EPS	-1.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	6.60
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.4780
Previous Close	0.4900
Day's Range	0.4780 - 0.4780
52-Week Range	0.2140 - 1.1600
Beta	n/a
RSI	50.58
Earnings Date	Mar 12, 2026

About Harvard Bioscience

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems f...

• Industry: Laboratory Analytical Instruments
• Founded: 1901
• Employees: 343
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HBI

Financial Performance

In 2024, Harvard Bioscience's revenue was $94.14 million, a decrease of -16.14% compared to the previous year's $112.25 million. Losses were -$12.41 million, 263.3% more than in 2023.

Financial numbers in USD